ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Sirolimus

Also written as “sirolimus”, “Rapamycin” and “Sirolimus for Injection (Albumin-bound)”.

Its studies are mostly in Renal Insufficiency · Kidney Failure, Chronic · Breast Neoplasms · Tuberous Sclerosis · Uveitis, led by 18 companies.

Drug pageSirolimus: every studyMany companies study it; this page follows only the 65 they lead. All 505 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 4, 200265 company-led studies, 15 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer260 open or runningphase 4since Sep 4, 2002May 17, 2002none ahead
CSPC Pharmaceutical Groupits history only85 open or runningphase 3since Apr 8, 2025Oct 25, 2021Oct 2027phase 1 · NCT06941142
Santen Pharmaceuticalits history only70 open or runningphase 3since May 19, 2011Nov 15, 2006none ahead
Astellas Pharmaits history only31 open or runningphase 4since May 31, 2011May 31, 2011Oct 31, 2027phase 2 · NCT07052929
Umoja Biopharmaits history only33 open or runningphase 2since Jul 24, 2026Jul 25, 2024Mar 2029phase 1 · NCT06528301
AgelessRxits history only21 open or runningphase 3since Dec 18, 2024Jul 13, 2020none ahead
Dr. Reddy's Laboratoriesits history only20 open or runningphase 1since Nov 18, 2014Nov 18, 2014none ahead
Hoffmann-La Rocheits history only20 open or runningphase 4since Jul 15, 2005Jul 15, 2005none ahead
Nobelpharmaits history only20 open or runningphase 1since Dec 3, 2018Dec 3, 2018none ahead
Vascular Therapiesits history only20 open or runningphase 3since Jul 29, 2015Jul 29, 2015none ahead
  • Named in CSPC Pharmaceutical Group’s own pipeline as sirolimus for injection (albumin-bound), phase 4, as of Aug 20, 2026 (source).

Also a collaborator on its studies: Basilea Pharmaceutica International and MacuSight.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since May 17, 2002.

  1. Sep 12, 2005Phase 4 study in Renal InsufficiencyNCT00195481 · 100 enrolled · India
  2. Nov 2, 2005Phase 3 study in Kidney DiseasesNCT00248313 · 470 enrolled
  3. Nov 11, 2005Phase 4 study in Renal InsufficiencyNCT00254709 · 66 enrolled
  4. Dec 2, 20052 phase 4 studies in Renal InsufficiencyNCT00261820, NCT00266123
  5. Jan 24, 2006Phase 4 study in Renal InsufficiencyNCT00282217 · 100 enrolled · Spain
  6. Apr 3, 2006Phase 3 study in AtherosclerosisNCT00311311 · 72 enrolled · United States, Canada
  7. Aug 25, 2006Phase 4 study in Renal InsufficiencyNCT00369382 · 121 enrolled · United States, Australia, Austria and more
  8. Jan 25, 2007Phase 3 study in Renal TransplantationNCT00428064 · 408 enrolled
  9. Mar 23, 2007Phase 4 study in Kidney TransplantationNCT00452361 · 31 enrolled · Taiwan
  10. May 7, 20072 phase 3 studiesNCT00470665, NCT00478608
  11. Jul 26, 2007Phase 2 study in Kidney TransplantationNCT00518271 · 120 enrolled
  12. Jul 26, 20073 phase 4 studies in Kidney TransplantationNCT00507793, NCT00519116, NCT00518375
  13. Apr 29, 2009Phase 4 study in Graft RejectionNCT00895583 · 254 enrolled · United States, Argentina, Australia and more
  14. Nov 5, 2010Phase 1 study in Transplant RejectionNCT01236378 · 24 enrolled · China

TargetBeta

“A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian …”NCIt, read by Claude
“FK506-binding protein 1A inhibitor”ChEMBL 37, by rule

Other programs on MTOR

ProgramCompanyFurthest phaseStudies
gedatolisibrulePfizerphase 39
PI3K/mTOR Kinase Inhibitor WXFL10030390ruleshanghai-jiatan-pharmatech-co-ltdphase 36
sapanisertibruleTakedaphase 214

Studies

All 26 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01236378Transplant Rejection · China1CompletedApr 201124
NCT00895583Graft Rejection · United States, Argentina, Australia and more4CompletedAug 2013254
NCT00519116Kidney Transplantation4Completed150
NCT00518375Kidney Transplantation4Completed250
NCT00518271Kidney Transplantation2Completed120
NCT00507793Kidney Transplantation4Completed385
NCT00478608Renal Transplant · Korea, Republic of3CompletedNov 200879
NCT00470665Renal Allograft Recipients3Completed460
NCT00452361Kidney Transplantation · Taiwan4TerminatedAug 200831
NCT00428064Renal Transplantation3Completed408
NCT00369382Renal Insufficiency · United States, Australia, Austria and more4CompletedApr 2010121
NCT00311311Atherosclerosis · United States, Canada3TerminatedDec 201072
NCT00282217Renal Insufficiency · Spain4Completed100
NCT00266123Renal Insufficiency4Completed420
NCT00261820Renal Insufficiency4Completed160
NCT00254709Renal Insufficiency4Completed66
NCT00248313Kidney Diseases3Completed470
NCT00195481Renal Insufficiency · India4CompletedDec 2005100
NCT00195273Graft vs Host Disease · Norway, Sweden3CompletedJul 200861
NCT00167947Renal Insufficiency · Italy3CompletedJul 2007150
NCT00137345Kidney Transplant · United States, Argentina, Australia and more3TerminatedAug 2006500
NCT00129961Skin Neoplasms · United States, Australia, Canada and more4CompletedJan 200986
NCT00086346Liver Transplantation · United States, Belgium, Canada and more3TerminatedJul 2008607
NCT00044720Kidney Failure, Chronic4CompletedJul 2005484
NCT00038948Renal Transplantation3CompletedMay 2008830
NCT00037531Graft vs Host Disease · United States, Canada3CompletedAug 2004769

How it is read

Names in the registry

  • “Sirolimus”, 28 entries
  • “sirolimus”, 8 entries
  • “Rapamycin”, 3 entries
  • “Sirolimus for Injection (Albumin-bound)”, 3 entries
  • “Rapamune® (Sirolimus)”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.